The Sample Processing and Immunoassay REsearch SPIRE Core (Core C) is designed to serve the RDRCC research community as a centralized resource for preparation and storage of clinically derived samples, for conducting a range of standard and innovative assays on clinically derived material and for serving as a conduit to other relevant research cores within the Institution. This core has facilitated, through disease-specific centers of excellence, the generation of large specimen bio-repositories recovered from well-pedigreed patient cohorts. In this manner, this well- established core, by providing biospecimen acquisition, processing, storage and retrieval services, has become a critical partner in enabling discovery at the translational interface, and in attracting the interest of a growing group of researchers. In addition, the high-quality assay services provided by Core C have resulted in numerous peer-reviewed publications, abstracts and investigator-initiated grant proposals. The assay capabilities in the Core play a critical role in pathway validation in human rheumatic disease cohorts.
The aims of this proposal are to sustain, grow and evolve this vital resource. We propose to expand the range of services offered to include innovative, cutting-edge technologies/approaches and serve as consultants and the pipeline to the necessary institutional expertise and resources that provide NextGen analytical approaches, and for advanced data analysis and interpretation. This interactive, dynamic framework has, and will continue to catalyze major leaps forward in research on the autoimmune rheumatic diseases. Core C will be directed by Drs. Casciola-Rosen and Soloski, both of whom have many years of experience in immunology, assay development, and directing high quality research responsive Cores. Drs. Andrade and Gutierrez, both of whom have many years of experience working with this Core team, will provide additional leadership. The close collaboration of this Core with the Administrative (Core A), Research Management and Patient Integrated Data (RAPID, Core B) and Data Science (Core D) Cores provides a powerful matrix to maximize synergies, resources and innovative collaborations in the environment.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Wohlfahrt, Alyssa; Bingham 3rd, Clifton O; Marder, Wendy et al. (2018) Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS) Measures in RA Patients Starting or Switching a DMARD. Arthritis Care Res (Hoboken) :
Darrah, Erika; Giles, Jon T; Davis, Ryan L et al. (2018) Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis. Front Immunol 9:2696
Leung, Ying Ying; Ogdie, Alexis; Orbai, Ana-Maria et al. (2018) Classification and Outcome Measures for Psoriatic Arthritis. Front Med (Lausanne) 5:246
Bartlett, S J; Gutierrez, A K; Butanis, A et al. (2018) Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. Qual Life Res 27:2443-2451
Darrah, Erika; Yu, Fang; Cappelli, Laura C et al. (2018) Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis. Arthritis Rheumatol :
Albayda, Jemima; Bingham 3rd, Clifton O; Shah, Ami A et al. (2018) Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatology (Oxford) 57:760-762
Cappelli, Laura C; Konig, Maximilian F; Gelber, Allan C et al. (2018) Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. Arthritis Res Ther 20:59
Igusa, Takeru; Hummers, Laura K; Visvanathan, Kala et al. (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77:1179-1186
Cappelli, Laura C; Brahmer, Julie R; Forde, Patrick M et al. (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553-557
Lee, Yvonne C; Bingham 3rd, Clifton O; Edwards, Robert R et al. (2018) Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Arthritis Care Res (Hoboken) 70:197-204

Showing the most recent 10 out of 22 publications